Overview

* Inotiv ( NOTV ) Q3 fiscal 2025 revenue rises 23.5% to $130.7 mln, beating expectations, per LSEG data

* Adjusted EBITDA for Q3 fiscal 2025 beats estimates, reaching $11.6 mln

* Company reports Q3 fiscal 2025 net loss of $17.6 mln

Result Drivers

* RMS GROWTH - Revenue from Research Models & Services rose 34.1%, driven by increased NHP-related product and service revenue

* DSA IMPROVEMENTS - Discovery & Safety Assessment revenue increased 8.9%, attributed to growth in general toxicology, biotherapeutic, and medical device services

* INVESTMENT BENEFITS - Integration and optimization investments over the past two years have driven growth in quoting and awards, per CEO Robert Leasure Jr.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $130.70 $127.10

Revenue mln mln (3

Analysts

)

Q3 Net -$17.60

Income mln

Q3 Beat $11.60 $11 mln

Adjusted mln (3

EBITDA Analysts

)

Q3 -$5.70

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Inotiv Inc ( NOTV ) is $5.00, about 58.5% above its August 5 closing price of $2.08

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)